Drug Costs

Assessing the Potential Impact of the Inflation Reduction Act on Federal and State Medicaid Prescription Drug Spending

The Inflation Reduction Act (P.L. 117-169) did not include any drug pricing provisions directly affecting Medicaid.  But as I have previously written for the Commonwealth Fund, Medicare drug pricing reforms can interact with the highly effective Medicaid Drug Rebate Program, under which drug manufacturers must pay sizable rebates to state Medicaid programs that significantly lower […]

Congress Could Consider Medicaid and CHIP Drug Pricing Provisions

The Inflation Reduction Act (P.L. 117-169), signed into law on August 16, 2022, includes historic Medicare drug pricing provisions such as a requirement for Medicare to directly negotiate prices with drug manufacturers for certain high-cost drugs and a requirement that drug manufacturers pay rebates to Medicare if their prices rise faster than inflation. Unfortunately, the […]

Build Back Better Act: Health Coverage Provisions Explained

On November 19, 2021, the House of Representatives passed the Build Back Better Act, the budget reconciliation bill, with the Senate expected to consider the legislation in coming weeks. The Build Back Better Act includes numerous provisions that would dramatically strengthen and expand both public and private health insurance coverage. Some of the new provisions […]

Build Back Better Reconciliation Bill Would Take Big Strides in Expanding Health Coverage and Access for Children and Families

[Editor’s Note: The U.S. House of Representatives approved a revised Build Back Better Act budget reconciliation bill on November 19, 2021. This brief  by Georgetown University CCF and CHIR explain the Medicaid, CHIP, and private health insurance provisions.]  Yesterday, the House Rules Committee unveiled a compromise reconciliation bill which includes numerous provisions that dramatically strengthen […]

Commonwealth Fund Blog Series on Medicaid Drug Pricing Issues

Congress and the Biden Administration are currently pursuing substantial drug pricing reforms as part of the reconciliation legislation expected to move this fall.  While the focus is primarily on Medicare, Medicaid should not be overlooked. In an ongoing series of posts for the Commonwealth Fund’s To the Point blog, I examine some key Medicaid drug […]